Coagulation abnormalities and vascular complications are common in PGM1-CDG
- PMID:38968673
- DOI: 10.1016/j.ymgme.2024.108530
Coagulation abnormalities and vascular complications are common in PGM1-CDG
Abstract
Phosphoglucomutase-1-congenital disorder of glycosylation (PGM1-CDG) is a rare genetic disorder caused by biallelic variants in the PGM1 gene, leading to the deficiency of the PGM1 enzyme. The most common clinical presentations include muscle involvement, failure to thrive, cleft palate, and cardiac involvement. Abnormal serum N-glycosylation, hypoglycemia, and liver function abnormalities including coagulation abnormalities are the most common laboratory abnormalities. While PGM1-CDG has been extensively studied, little is known about the extent of the coagulation abnormalities in individuals with PGM1-CDG. Unlike most CDG, some symptoms of PGM1-CDG are treatable with D-galactose (D-gal) supplementation, though reliable clinical endpoints are necessary to appropriately evaluate the potential improvement with D-gal in PGM1-CDG. Here, we aimed to describe the incidence of coagulation abnormalities in PGM1-CDG and their evolution, their relation to clinical events, and the ability of D-gal treatment to improve them. A retrospective analysis was conducted on 73 reported individuals. All individuals had a molecularly confirmed PGM1-CDG diagnosis. All incidences of antithrombin (AT), aPTT, PT, factor (F) XI, FX, FIX, FVII, protein C and protein S data and major clinical events related to coagulation abnormalities, were collected. Coagulation information was available for only 58.9 % of the reported individuals, out of which 67.4 % of PGM1-CDG individuals were reported to have abnormalities. The most frequently observed abnormality was AT (mean: 30.8% R:80-120 %) deficiency. Four individuals had major thrombotic events. Coagulation status on D-gal treatment, were reported in 19 individuals. Several factors showed improvement including AT (mean: 64.5 %), indicating galactose is beneficial in treating coagulation abnormalities in PGM1-CDG. Due to the scarcity of the reported data on coagulation parameters, we also evaluated data collected in sixteen PGM1-CDG individuals enrolled in the FCDGC Natural History Study. Longitudinal data showed improvements in several coagulant parameters and disease severity improved for almost all patients of whom we had multiple datapoints on D-gal. AT showed significant improvement on D-gal. We conclude that coagulation abnormalities are frequently present in PGM1-CDG and show improvement on D-gal. We recommend coagulation parameters should be routinely checked in individuals with PGM1-CDG or suspected of having PGM1-CDG. Finally, AT may be used as a primary or secondary clinical endpoint for upcoming clinical trials in PGM1-CDG individuals.
Keywords: Coagulation abnormalities; Congenital disorder(s) of glycosylation; Galactose therapy; Phosphoglucomutase-1.
Copyright © 2023. Published by Elsevier Inc.
Conflict of interest statement
Declaration of competing interest None.
Similar articles
- Novel insights into the phenotype and long-term D-gal treatment in PGM1-CDG: a case series.Radenkovic S, Johnsen C, Schulze A, Lail G, Guilder L, Schwartz K, Schultz M, Mercimek-Andrews S, Boyer S, Morava E.Radenkovic S, et al.Ther Adv Rare Dis. 2023 Jan 26;4:26330040221150269. doi: 10.1177/26330040221150269. eCollection 2023 Jan-Dec.Ther Adv Rare Dis. 2023.PMID:37181075Free PMC article.
- Oral D-galactose supplementation in PGM1-CDG.Wong SY, Gadomski T, van Scherpenzeel M, Honzik T, Hansikova H, Holmefjord KSB, Mork M, Bowling F, Sykut-Cegielska J, Koch D, Hertecant J, Preston G, Jaeken J, Peeters N, Perez S, Nguyen DD, Crivelly K, Emmerzaal T, Gibson KM, Raymond K, Abu Bakar N, Foulquier F, Poschet G, Ackermann AM, He M, Lefeber DJ, Thiel C, Kozicz T, Morava E.Wong SY, et al.Genet Med. 2017 Nov;19(11):1226-1235. doi: 10.1038/gim.2017.41. Epub 2017 Jun 15.Genet Med. 2017.PMID:28617415Free PMC article.Clinical Trial.
- Phosphoglucomutase-1 deficiency: Early presentation, metabolic management and detection in neonatal blood spots.Conte F, Morava E, Bakar NA, Wortmann SB, Poerink AJ, Grunewald S, Crushell E, Al-Gazali L, de Vries MC, Mørkrid L, Hertecant J, Brocke Holmefjord KS, Kronn D, Feigenbaum A, Fingerhut R, Wong SY, van Scherpenzeel M, Voermans NC, Lefeber DJ.Conte F, et al.Mol Genet Metab. 2020 Sep-Oct;131(1-2):135-146. doi: 10.1016/j.ymgme.2020.08.003. Epub 2020 Sep 17.Mol Genet Metab. 2020.PMID:33342467
- Galactose supplementation in phosphoglucomutase-1 deficiency; review and outlook for a novel treatable CDG.Morava E.Morava E.Mol Genet Metab. 2014 Aug;112(4):275-9. doi: 10.1016/j.ymgme.2014.06.002. Epub 2014 Jun 21.Mol Genet Metab. 2014.PMID:24997537Free PMC article.Review.
- Central nervous involvement is common in PGM1-CDG.Radenkovic S, Witters P, Morava E.Radenkovic S, et al.Mol Genet Metab. 2018 Nov;125(3):200-204. doi: 10.1016/j.ymgme.2018.08.008. Epub 2018 Aug 21.Mol Genet Metab. 2018.PMID:30262252Review.
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous